Probucol prevents blood-brain barrier dysfunction in wild-type mice induced by saturated fat or cholesterol feeding

Clinical and Experimental Pharmacology and Physiology

Volumn 40, Issue 1, 2013, Pages 45-52

  Takechi, Ryusuke ^a,b   Galloway, Susan ^a   Pallebage Gamarallage, Menuka M ^a   Lam, Virginie ^a   Dhaliwal, Satvinder S ^a,b   Mamo, John C ^a,b  

^a CURTIN UNIVERSITY   (Australia)

^b Australian Technology Network   (Australia)

Author keywords

Blood brain barrier; Cholesterol; Neuroinflam mation; Probucol; Saturated fatty acid; Vascular dementia

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN B; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN; LIPID; PROBUCOL; SATURATED FATTY ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CHOLESTEROL INTAKE; CONTROLLED STUDY; DRUG EFFICACY; EXTRAVASATION; FEMALE; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS B; BLOOD-BRAIN BARRIER; CEREBROVASCULAR DISORDERS; CHOLESTEROL, DIETARY; DIET; DIETARY FATS; FATTY ACIDS; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPOLIPIDEMIC AGENTS; IMMUNOGLOBULINS; INFLAMMATION; LIPOPROTEINS; MICE; MICE, INBRED C57BL; PROBUCOL; RANDOM ALLOCATION;

EID: 84871678869     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12032     Document Type: Article

References (52)

1. Kalaria RN. Vascular basis for brain degeneration: Faltering controls and risk factors for dementia. Nutr. Rev. 2010; 68 (Suppl. 2): S74-87.
2. Miyakawa T. Vascular pathology in Alzheimer's disease. Psychogeriatrics 2010; 10: 39-44.
3. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201.
4. Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch. Neurol. 1990; 47: 1210-6.
5. Meucci G, Rossi G, Bettini R et al. Laser nephelometric evaluation of albumin, IgG and alpha 2-macroglobulin: Applications to the study of alterations of the blood-brain barrier. J. Neurol. Sci. 1993; 118: 73-8.
6. Dickstein DL, Walsh J, Brautigam H, Stockton SD Jr, Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J. Med. 2010; 77: 82-102.
7. Pasinetti GM, Eberstein JA. Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. J. Neurochem. 2008; 106: 1503-14.
8. Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JC. Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog. Lipid Res. 2010; 49: 159-70.
9. Kalmijn S. Fatty acid intake and the risk of dementia and cognitive decline: A review of clinical and epidemiological studies. J. Nutr. Health Aging 2000; 4: 202-7.
10. Petot GJ, Friedland RP. Lipids, diet and Alzheimer disease: An extended summary. J. Neurol. Sci. 2004; 226: 31-3.
11. Ghribi O, Golovko MY, Larsen B, Schrag M, Murphy EJ. Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J. Neurochem. 2006; 99: 438-49.
12. Takechi R, Galloway S, Pallebage-Gamarallage MM et al. Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-beta. Br. J. Nutr. 2010; 103: 652-62.
13. Cole GM, Frautschy SA. Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model. Nutr. Health 2006; 18: 249-59.
14. Oksman M, Iivonen H, Hogyes E et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 2006; 23: 563-72.
15. Pal S, Allister E, Thomson A, Mamo JC. Cholesterol esters regulate apoB48 secretion in CaCo2 cells. Atherosclerosis 2002; 161: 55-63.
16. Galloway S, Jian L, Johnsen R, Chew S, Mamo JC. β-Amyloid or its precursor protein is found in epithelial cells of the small intestine and is stimulated by high-fat feeding. J. Nutr. Biochem. 2007; 18: 279-84.
17. Pallebage-Gamarallage MM, Galloway S, Johnsen R, Jian L, Dhaliwal S, Mamo JC. The effect of exogenous cholesterol and lipid-modulating agents on enterocytic amyloid-beta abundance. Br. J. Nutr. 2009; 101: 340-7.
18. Takechi R, Galloway S, Pallebage-Gamarallage MM, Mamo JC. Chylomicron amyloid-beta in the aetiology of Alzheimer's disease. Atheroscler. Suppl. 2008; 9: 19-25.
19. Burgess BL, McIsaac SA, Naus KE et al. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant Aβ in plasma. Neurobiol. Dis. 2006; 24: 114-27.
20. Namba Y, Tsuchiya H, Ikeda K. Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with Alzheimer's disease. Neurosci. Lett. 1992; 134: 264-6.
21. Takechi R, Galloway S, Pallebage-Gamarallage M, Wellington C, Johnsen R, Mamo JC. Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice. Histochem. Cell Biol. 2009; 131: 661-6.
22. Tanous D, Hime N, Stocker R. Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds. Redox Rep. 2008; 13: 48-59.
23. Heinecke JW. Lipoprotein oxidation in cardiovascular disease: Chief culprit or innocent bystander? J. Exp. Med. 2006; 203: 813-6.
24. Pallebage-Gamarallage MM, Galloway S, Takechi R, Dhaliwal S, Mamo JC. Probucol suppresses enterocytic accumulation of amyloid-beta induced by saturated fat and cholesterol feeding. Lipids 2012; 47: 27-34.
25. Mamo JC, Elsegood CL, Umeda Y, Hirano T, Redgrave TG. Effect of probucol on plasma clearance and organ uptake of chylomicrons and VLDLs in normal and diabetic rats. Arterioscler. Thromb. 1993; 13: 231-9.
26. Cho DH, Nakamura T, Lipton SA. Mitochondrial dynamics in cell death and neurodegeneration. Cell. Mol. Life Sci. 2010; 67: 3435-47.
27. Nerurkar PV, Johns LM, Buesa LM et al. Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J. Neuroinflammation 2011; 8: 64.
28. Russell JC, Graham SE, Amy RM, Dolphin PJ. Cardioprotective effect of probucol in the atherosclerosis-prone JCR:LA-cp rat. Eur. J. Pharmacol. 1998; 350: 203-10.
29. Takechi R, Galloway S, Pallebage-Gamarallage MM, Johnsen RD, Mamo JC. Three-dimensional immunofluorescent double labelling using polyclonal antibodies derived from the same species: Enterocytic colocalization of chylomicrons with Golgi apparatus. Histochem. Cell Biol. 2008; 129: 779-84.
30. Smith D, Proctor SD, Mamo JC. A highly sensitive assay for quantitation of apolipoprotein B48 using an antibody to human apolipoprotein B and enhanced chemiluminescence. Ann. Clin. Biochem. 1997; 34: 185-9.
31. Marchi N, Cavaglia M, Fazio V, Bhudia S, Hallene K, Janigro D. Peripheral markers of blood-brain barrier damage. Clin. Chim. Acta 2004; 342: 1-12.
32. Petzold A, Brassat D, Mas P et al. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult. Scler. 2004; 10: 281-3.
33. Pallebage-Gamarallage MM, Lam V, Takechi R, Galloway S, Mamo JCA. Diet enriched in docosahexanoic acid exacerbates brain parenchymal extravasation of apo B lipoproteins induced by chronic ingestion of saturated fats. Int. J. Vasc. Med. 2012; 2012: 647689.
34. Lam V, Takechi R, Pallebage-Gamarallage MM, Galloway S, Mamo JC. Colocalisation of plasma derived apo B lipoproteins with cerebral proteoglycans in a transgenic-amyloid model of Alzheimer's disease. Neurosci. Lett. 2011; 492: 160-4.
35. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995; 44: 863-70.
36. Studzinski CM, Li F, Bruce-Keller AJ et al. Effects of short-term Western diet on cerebral oxidative stress and diabetes related factors in APP × PS1 knock-in mice. J. Neurochem. 2009; 108: 860-6.
37. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: An update. Clin. Endocrinol. 2006; 64: 355-65.
38. Wassall SR, Brzustowicz MR, Shaikh SR, Cherezov V, Caffrey M, Stillwell W. Order from disorder, corralling cholesterol with chaotic lipids. The role of polyunsaturated lipids in membrane raft formation. Chem. Phys. Lipids 2004; 132: 79-88.
39. Wassall SR, Stillwell W. Polyunsaturated fatty acid-cholesterol interactions: Domain formation in membranes. Biochim. Biophys. Acta 2009; 1788: 24-32.
40. Diaz O, Berquand A, Dubois M et al. The mechanism of docosahexaenoic acid-induced phospholipase D activation in human lymphocytes involves exclusion of the enzyme from lipid rafts. J. Biol. Chem. 2002; 277: 39368-78.
41. Morgan NG. Fatty acids and beta-cell toxicity. Curr. Opin. Clin. Nutr. Metab. Care 2009; 12: 117-22.
42. Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr. Biol. 2009; 19: R1046-52.
43. Patil S, Balu D, Melrose J, Chan C. Brain region-specificity of palmitic acid-induced abnormalities associated with Alzheimer's disease. BMC Res. Notes 2008; 1: 20.
44. Diakogiannaki E, Morgan NG. Differential regulation of the ER stress response by long-chain fatty acids in the pancreatic beta-cell. Biochem. Soc. Trans. 2008; 36: 959-62.
45. Takechi R, Pallebage-Gamarallage MM, Lam V, Giles C, Mamo JC. Aging-related changes in blood-brain barrier integrity and the effect of dietary fat. Neurodegener. Dis. 2012; Epub 2 November 2012
46. Yao PM, Tabas I. Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway. J. Biol. Chem. 2001; 276: 42468-76.
47. Peng SK, Tham P, Taylor CB, Mikkelson B. Cytotoxicity of oxidation derivatives of cholesterol on cultured aortic smooth muscle cells and their effect on cholesterol biosynthesis. Am. J. Clin. Nutr. 1979; 32: 1033-42.
48. Pallebage-Gamarallage MM, Takechi R, Lam V, Galloway S, Dhaliwal S, Mamo JC. Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk. Atheroscler. Suppl. 2010; 11: 49-54.
49. Grin'kina NM, Karnabi EE, Damania D, Wadgaonkar S, Muslimov IA, Wadgaonkar R. Sphingosine kinase 1 deficiency exacerbates LPS-induced neuroinflammation. PLoS ONE 2012; 7: e36475.
50. Champagne D, Pearson D, Dea D, Rochford J, Poirier J. The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: Implications for Alzheimer's disease. Neuroscience 2003; 121: 99-110.
51. Santos DB, Peres KC, Ribeiro RP et al. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid beta peptide in mice. Exp. Neurol. 2012; 233: 767-75.
52. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol. Med. 2003; 9: 94-101.